Clinical Supply Agreement Template for the United States
Generate a bespoke document
What is a Clinical Supply Agreement?
A Clinical Supply Agreement is essential when a company needs to secure reliable manufacturing and supply of investigational products for clinical trials in the United States. This agreement addresses critical aspects such as quality standards, regulatory compliance, manufacturing processes, testing requirements, and supply chain management. It ensures adherence to FDA regulations, GMP requirements, and other applicable healthcare laws while protecting both parties' interests through clearly defined terms and conditions.
Frequently Asked Questions
Is a Clinical Supply Agreement legally enforceable in the United States?
Yes, a Clinical Supply Agreement is a legally binding contract in the United States when properly executed by both parties. These agreements are governed by federal contract law and must comply with FDA regulations under 21 CFR Part 312 for investigational new drugs. The contract creates enforceable obligations between sponsors and manufacturers regarding clinical trial supply chain management.
Can FDA shut down my clinical trial if my supply agreement is missing or incomplete?
Yes, the FDA can place a clinical trial on hold or issue a Form 483 if your Clinical Supply Agreement fails to demonstrate adequate manufacturing controls or regulatory compliance. Under 21 CFR 312.44, sponsors must ensure proper manufacturing and supply chain documentation. Incomplete agreements may indicate insufficient oversight of investigational product quality and safety.
Does my Clinical Supply Agreement need to include FDA Good Manufacturing Practice compliance?
Yes, Clinical Supply Agreements in the United States must include provisions ensuring compliance with FDA's Good Manufacturing Practice (GMP) regulations under 21 CFR Parts 210 and 211. The agreement should specify manufacturing standards, quality control procedures, and documentation requirements. Both parties must commit to maintaining GMP compliance throughout the clinical trial period.
How is a Clinical Supply Agreement different from a regular manufacturing contract?
A Clinical Supply Agreement includes specific FDA regulatory compliance requirements that standard manufacturing contracts lack. These agreements must address investigational product handling, clinical trial material labeling under 21 CFR 312.6, and adverse event reporting obligations. Unlike commercial manufacturing contracts, they also require provisions for FDA inspections and regulatory documentation.
How long does it typically take to negotiate a Clinical Supply Agreement?
Clinical Supply Agreement negotiations typically take 3-6 months in the United States due to complex regulatory and liability provisions. The timeline depends on FDA compliance requirements, manufacturing complexity, and risk allocation negotiations. Rush agreements for urgent clinical trials may be completed in 4-8 weeks but require experienced legal counsel to avoid regulatory pitfalls.
Why do Clinical Supply Agreements get rejected during FDA inspections?
FDA inspectors commonly find Clinical Supply Agreements lacking adequate quality control provisions, insufficient manufacturing oversight clauses, or missing adverse event reporting procedures. Many agreements fail to properly address 21 CFR Part 312 requirements or lack clear accountability for Good Manufacturing Practice compliance. Vague liability and indemnification clauses also raise regulatory concerns.
Can my Clinical Supply Agreement protect me from FDA enforcement actions?
A well-drafted Clinical Supply Agreement can provide some protection by demonstrating due diligence and proper oversight, but it cannot shield you from direct FDA enforcement actions. The agreement should include compliance representations, audit rights, and clear responsibility allocation under federal regulations. However, sponsors remain ultimately responsible for investigational product quality and regulatory compliance regardless of contractual provisions.
About the Clinical Supply Agreement
A Clinical Supply Agreement establishes the legal framework between pharmaceutical companies, contract manufacturers, and research organizations for supplying investigational products during clinical trials. This contract ensures your clinical trial supply chain meets stringent regulatory requirements while protecting all parties involved in the manufacturing and distribution process.
When do you need this document?
You need a Clinical Supply Agreement when initiating any clinical trial requiring manufactured investigational products. This includes Phase I through Phase III trials where a pharmaceutical sponsor contracts with a Contract Manufacturing Organization to produce clinical supplies, when research institutions need specialized manufacturing for investigational compounds, or when multiple parties collaborate on clinical research requiring controlled substance distribution. The agreement becomes essential when transferring manufacturing responsibilities from internal facilities to external contractors, ensuring regulatory compliance throughout the supply chain. You also need this document when establishing backup manufacturing arrangements to prevent clinical trial delays due to supply shortages.
Key legal considerations
Quality requirements form the cornerstone of any Clinical Supply Agreement, mandating strict adherence to Good Manufacturing Practice standards and FDA quality control protocols. Manufacturing specifications must be precisely defined, including batch records, testing requirements, and release criteria that comply with 21 CFR Part 312 regulations. Intellectual property protection clauses safeguard proprietary formulations and manufacturing processes while maintaining confidentiality throughout the supply relationship. Liability allocation provisions address potential product defects, regulatory violations, and clinical trial delays, with indemnification clauses protecting parties from third-party claims. Supply chain security measures must address drug serialization requirements, cold chain maintenance for biologics, and secure transportation protocols. Regulatory compliance sections ensure both parties maintain current FDA registrations, implement proper change control procedures, and facilitate regulatory inspections when required.
Legal requirements in United States
United States Clinical Supply Agreements must comply with the comprehensive Food, Drug, and Cosmetic Act framework governing pharmaceutical manufacturing and distribution. Manufacturers must maintain current FDA registration and comply with 21 CFR Part 210 and 211 Good Manufacturing Practice regulations throughout the supply period. The agreement must address Investigational New Drug application requirements under 21 CFR Part 312, ensuring proper documentation and regulatory reporting. HIPAA compliance provisions protect patient privacy when clinical supplies contain identifying information or require special handling protocols. Public Health Service Act requirements apply when dealing with biological products, mandating additional safety and efficacy documentation. The contract must establish clear procedures for FDA inspections, adverse event reporting, and regulatory correspondence, ensuring seamless communication between all parties and regulatory authorities.
GOVERNING LAW
Applicable law
This Clinical Supply Agreement is drafted to comply with United States law. Key legislation includes:
Explore 208,390+ legal templates
Explore 208,390+ legal templates
Genie's Security Promise
Genie is the safest place to draft. Here's how we prioritise your privacy and security.
Your data is private:
We do not train on your data; Genie's AI improves independently
All data stored on Genie is private to your organisation
Your documents are protected:
Your documents are protected by ultra-secure 256-bit encryption
We are ISO27001 certified, so your data is secure
Organizational security:
You retain IP ownership of your documents and their information
You have full control over your data and who gets to see it